|
1
|
Niu HY, Niu CY, Wang JH, Zhang Y and He P:
Health-related quality of life in women with breast cancer: A
literature-based review of psychometric properties of breast
cancer-specific measures. Asian Pac J Cancer Prev. 15:3533–3536.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lee Katie SY and Knobf MT: Primary breast
cancer decision-making among Chinese American Women: Satisfaction,
regret. Nurs Res. 64:391–401. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shao S and Zhao X, Zhang X, Luo M, Zuo X,
Huang S, Wang Y, Gu S and Zhao X: Notch1 signaling regulates the
epithelial-mesenchymal transition and invasion of breast cancer in
a Slug-dependent manner. Mol Cancer. 14:282015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Xiao X, Chen B, Liu X, Liu P, Zheng G, Ye
F, Tang H and Xie X: Diallyl disulfide suppresses SRC/Ras/ERK
signaling-mediated proliferation and metastasis in human breast
cancer by up-regulating miR-34a. PLoS One. 9:e1127202014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Su B, Su J, Zeng Y, Liu F, Xia H, Ma YH,
Zhou ZG, Zhang S, Yang BM, Wu YH, et al: Diallyl disulfide
suppresses epithelial-mesenchymal transition, invasion and
proliferation by downregulation of LIMK1 in gastric cancer.
Oncotarget. 7:10498–10512. 2016.PubMed/NCBI
|
|
6
|
Lai KC, Hsu SC, Kuo CL, Yang JS, Ma CY, Lu
HF, Tang NY, Hsia TC, Ho HC and Chung JG: Diallyl sulfide, diallyl
disulfide, and diallyl trisulfide inhibit migration and invasion in
human colon cancer colo 205 cells through the inhibition of matrix
metalloproteinase-2, −7, and −9 expressions. Environ Toxicol.
28:479–488. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Luo N, Zhao LC, Shi QQ, Feng ZQ, Chen DL
and Li J: Induction of apoptosis in human leukemic cell lines by
diallyl disulfide via modulation of EGFR/ERK/PKM2 signaling
pathways. Asian Pac J Cancer Prev. 16:3509–3515. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Huang J, Yang B, Xiang T, Peng W, Qiu Z,
Wan J, Zhang L, Li H, Li H and Ren G: Diallyl disulfide inhibits
growth and metastatic potential of human triple-negative breast
cancer cells through inactivation of the β-catenin signaling
pathway. Mol Nutr Food Res. 59:1063–1075. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ciocci M, Iorio E, Carotenuto F, Khashoggi
HA, Nanni F and Melino S: H2S-releasing nanoemulsions: A new
formulation to inhibit tumor cells proliferation and improve tissue
repair. Oncotarget. 7:84338–84358. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yi L, Shan J, Chen X, Li G, Li L, Tan H
and Su Q: Involvement of calreticulin in cell proliferation,
invasion and differentiation in diallyl disulfide-treated HL-60
cells. Oncol Lett. 12:1861–1867. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Su B, Su J, He H, Wu Y, Xia H, Zeng X, Dai
W, Ai X, Ling H, Jiang H and Su Q: Identification of potential
targets for diallyl disulfide in human gastric cancer MGC-803 cells
using proteomics approaches. Oncol Rep. 33:2484–2494. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sun Y, Wang X, Zhou Q, Lu Y, Zhang H, Chen
Q, Zhao M and Su S: Inhibitory effect of emodin on migration,
invasion and metastasis of human breast cancer MDA-MB-231 cells in
vitro and in vivo. Oncol Rep. 33:338–346. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jacob A and Prekeris R: The regulation of
MMP targeting to invadopodia during cancer metastasis. Front Cell
Dev Biol. 3:42015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lampelj M, Arko D, Cas-Sikosek N, Kavalar
R, Ravnik M, Jezersek-Novakovic B, Dobnik S, Dovnik NF and Takac I:
Urokinase plasminogen activator (uPA) and plasminogen activator
inhibitor type-1 (PAI-1) in breast cancer-correlation with
traditional prognostic factors. Radiol Oncol. 49:357–364. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Melanson BD, Bose R, Hamill JD, Marcellus
KA, Pan EF and McKay BC: The role of mRNA decay in p53 induced gene
expression. RNA. 17:2222–2234. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Brooks SA and Blackshear PJ:
Tristetraprolin (TTP): Interactions with mRNA and proteins, and
current thoughts on mechanisms of action. Biochim Biophys Acta.
1829:666–679. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Barrios-García T, Tecalco-Cruz A,
Gómez-Romero V, Reyes-Carmona S, Meneses-Morales I and León-Del-Río
A: Tristetraprolin represses estrogen receptor α transactivation in
breast cancer cells. J Biol Chem. 289:15554–15565. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tran DDH, Koch A, Allister A, Saran S,
Ewald F, Koch M, Nashan B and Tamura T: Treatment with MAPKAP2
(MK2) inhibitor and DNA methylation inhibitor, 5-aza dC,
synergistically triggers apoptosis in hepatocellular carcinoma
(HCC) via tristetraprolin (TTP). Cell Signal. 28:1872–1880. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Van Tubergen EA, Banerjee R, Liu M, Vander
Broek R, Light E, Kuo S, Feinberg SE, Willis AL, Wolf G, Carey T,
et al: Inactivation or loss of TTP promotes invasion in head and
neck cancer via transcript stabilization and secretion of MMP9,
MMP2, and IL-6. Clin Cancer Res. 19:1169–1179. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Redig AJ and McAllister SS: Breast cancer
as a systemic disease: A view of metastasis. J Intern Med.
274:113–126. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Warrier S, Tapia G, Goltsman D and Beith
J: An update in breast cancer screening and management. Womens
Health (Lond). 12:229–239. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lei XY, Yao SQ, Zu XY, Huang ZX, Liu LJ,
Zhong M, Zhu BY, Tang SS and Liao DF: Apoptosis induced by diallyl
disulfide in human breast cancer cell line MCF-7. Acta Pharmacol
Sin. 29:1233–1239. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang G, Liu G, Ye Y, Fu Y and Zhang X:
Upregulation of miR-34a by diallyl disulfide suppresses invasion
and induces apoptosis in SGC-7901 cells through inhibition of the
PI3K/Akt signaling pathway. Oncol Lett. 11:2661–2667. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pei S, Yang X, Wang H, Zhang H, Zhou B,
Zhang D and Lin D: Plantamajoside, a potential anti-tumor herbal
medicine inhibits breast cancer growth and pulmonary metastasis by
decreasing the activity of matrix metalloproteinase-9 and −2. BMC
Cancer. 15:9652015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Noh H, Hong S and Huang S: Role of
urokinase receptor in tumor progression and development.
Theranostics. 3:487–495. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Page-McCaw A, Ewald AJ and Werb Z: Matrix
metalloproteinases and the regulation of tissue remodelling. Nat
Rev Mol Cell Biol. 8:221–233. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Moirangthem A, Bondhopadhyay B, Mukherjee
M, Bandyopadhyay A, Mukherjee N, Konar K, Bhattacharya S and Basu
A: Simultaneous knockdown of uPA and MMP9 can reduce breast cancer
progression by increasing cell-cell adhesion and modulating EMT
genes. Sci Rep. 6:219032016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shi C, Zhang N, Feng Y, Cao J, Chen X and
Liu B: Aspirin inhibits IKK-β-mediated prostate cancer cell
invasion by targeting matrix Metalloproteinase-9 and Urokinase-Type
plasminogen activator. Cell Physiol Biochem. 41:1313–1324. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tong W, Wang Q, Sun D and Suo J: Curcumin
suppresses colon cancer cell invasion via AMPK-induced inhibition
of NF-κB, uPA activator and MMP9. Oncol Lett. 12:4139–4146. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Guo J, Qu H, Chen Y and Xia J: The role of
RNA-binding protein tristetraprolin in cancer and immunity. Med
Oncol. 34:1962017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Griseri P, Bourcier C, Hieblot C,
Essafi-Benkhadir K, Chamorey E, Touriol C and Pagès G: A synonymous
polymorphism of the Tristetraprolin (TTP) gene, an AU-rich
mRNA-binding protein, affects translation efficiency and response
to Herceptin treatment in breast cancer patients. Hum Mol Genet.
20:4556–4568. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sobolewski C, Sanduja S, Blanco FF, Hu L
and Dixon DA: Histone deacetylase inhibitors activate
tristetraprolin expression through induction of early growth
response protein 1 (EGR1) in colorectal cancer cells. Biomolecules.
5:2035–2055. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pandiri I, Chen Y, Joe Y, Kim HJ, Park J,
Chung HT and Park JW: Tristetraprolin mediates the
anti-proliferative effects of metformin in breast cancer cells.
Breast Cancer Res Treat. 156:57–64. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ryu J, Yoon NA, Lee YK, Jeong JY, Kang S,
Seong H, Choi J, Park N, Kim N, Cho WJ, et al: Tristetraprolin
inhibits the growth of human glioma cells through downregulation of
urokinase plasminogen activator/urokinase plasminogen activator
receptor mRNAs. Mol Cells. 38:156–162. 2015.PubMed/NCBI
|
|
35
|
Prabhala P and Ammit AJ: Tristetraprolin
and its role in regulation of airway inflammation. Mol Pharmacol.
87:629–638. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gebeshuber CA, Zatloukal K and Martinez J:
miR-29a suppresses tristetraprolin, which is a regulator of
epithelial polarity and metastasis. EMBO Rep. 10:400–405. 2009.
View Article : Google Scholar : PubMed/NCBI
|
